AAP
NTLA icon

Arax Advisory Partners’s Intellia Therapeutics NTLA Stock Holding History

Arax Advisory Partners’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$86.1K Buy
5,086
+4,538
+828% +$63.5K ﹤0.01% 2847
2026
Q1 		$7.03K Sell
548
-465
-46% -$5.92K ﹤0.01% 2636
2025
Q4 		$9.11K Sell
1,013
-1,622
-62% -$22.3K ﹤0.01% 2520
2025
Q3 		$45.5K Buy
2,635
+2,534
+2,509% +$31.2K ﹤0.01% 1871
2025
Q2 		$948 Buy
+101
New +$829 ﹤0.01% 2796

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Arax Advisory Partners's NTLA Position: Q2 2026 in Review

Arax Advisory Partners increased its Intellia Therapeutics (NTLA) stake by 828% in Q2 2026, buying an estimated $63.5K and bringing the position to 5,086 shares worth $86.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2847.

Arax Advisory Partners first reported a position in NTLA in Q2 2025 and has held it in 5 quarters since. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Arax Advisory Partners held 5,086 shares of Intellia Therapeutics worth $86.1K as of Q2 2026.
  • Arax Advisory Partners bought 4,538 Intellia Therapeutics shares in Q2 2026, an estimated $63.5K.
  • Intellia Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2847 holding.
  • Arax Advisory Partners first reported a position in Intellia Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.